Harrow Health (NASDAQ:HROW) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price target of $10.75 for the company and are forecasting that the company will post $0.12 EPS for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 93 out of 255 based on the ratings given to related companies.
A number of research firms recently weighed in on HROW. Zacks Investment Research lowered shares of Harrow Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. ValuEngine downgraded shares of Harrow Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th.
NASDAQ:HROW traded up $0.05 during midday trading on Friday, reaching $4.55. The company had a trading volume of 195,549 shares, compared to its average volume of 318,584. Harrow Health has a 12-month low of $1.88 and a 12-month high of $7.20. The firm has a market cap of $111.08 million, a PE ratio of 7.46 and a beta of 0.02. The company has a current ratio of 2.76, a quick ratio of 2.61 and a debt-to-equity ratio of 0.48.
Harrow Health (NASDAQ:HROW) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.07). The company had revenue of $11.38 million during the quarter, compared to analyst estimates of $10.92 million. Harrow Health had a net margin of 35.35% and a return on equity of 177.27%. Equities analysts forecast that Harrow Health will post -0.02 EPS for the current year.
In related news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $6.91, for a total value of $69,100.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 30,000 shares of company stock worth $175,400 over the last 90 days. Company insiders own 13.78% of the company’s stock.
Harrow Health Company Profile
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Further Reading: How Investors Can Profit from Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.